Human Pathology
Volume 43, Issue 2 , Pages 153-164 , February 2012

Erythroid proliferations in myeloid neoplasms

  • Sa A. Wang

      Affiliations

    • Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    • Corresponding Author InformationCorresponding author.
    • ,
  • Robert P. Hasserjian

      Affiliations

    • Department of Pathology, Massachusetts General Hospital, Boston, MA 02114, USA

Received 6 July 2011 ,Revised 10 August 2011 ,Accepted 12 August 2011.

References 

  1. Di Guglielmo G. Richerche di ematologia. I. Un caso di eritroleucemia. Megacariociti in circolo e loro funzione piastrinopoietico. Folia Medica. 1917;13:386
  2. Grimwade D, Hills RK, Moorman AV, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010;116:354–365
  3. Di Guglielmo G. Le Malatte Eritremiche ed Eritroleucemiche II Pensiero Scientifico. 1962;Rome
  4. Galton DAG, Dacie JV, Peto R. The relationship between morphology and other features of acute myeloid leukaemia and their prognostic significance. Report on the Medical Research Council's Working Party on Leukaemia in Adults. Br J Haematol. 1975;31:165–180
  5. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol. 1976;33:451–458
  6. Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Inter Med. 1985;103:620–625
  7. Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting—Airlie House, Virginia, November 1997. J Clin Oncol. 1999;17:3835–3849
  8. Hasserjian RP, Howard J, Wood A, Henry K, Bain B. Acute erythremic myelosis (true erythroleukaemia): a variant of AML FAB-M6. J Clin Pathol. 2001;54:205–209
  9. Kowal-Vern A, Mazzella FM, Cotelingam JD, et al. Diagnosis and characterization of acute erythroleukemia subsets by determining the percentages of myeloblasts and proerythroblasts in 69 cases. Am J Hematol. 2000;65:5–13
  10. Garand R, Duchayne E, Blanchard D, et al. Minimally differentiated erythroleukaemia (AML M6 ‘variant’): a rare subset of AML distinct from AML M6. Groupe Francais d'Hematologie Cellulaire. Br J Haematol. 1995;90:868–875
  11. Kowal-Vern A, Cotelingam J, Schumacher HR. The prognostic significance of proerythroblasts in acute erythroleukemia. Am J Clin Pathol. 1992;98:34–40
  12. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51:189–199
  13. Mazzella FM, Alvares C, Kowal-Vern A, Schumacher HR. The acute erythroleukemias. Clin Lab Med. 2000;20:119–137
  14. Mazzella FM, Kowal-Vern A, Shrit MA, et al. Acute erythroleukemia: evaluation of 48 cases with reference to classification, cell proliferation, cytogenetics, and prognosis. Am J Clin Pathol. 1998;110:590–598
  15. Domingo-Claros A, Larriba I, Rozman M, et al. Acute erythroid neoplastic proliferations. A biological study based on 62 patients. Haematologica. 2002;87:148–153
  16. Mazzella FM, Smith D, Horn P, et al. Prognostic significance of pronormoblasts in erythrocyte predominant myelodysplastic patients. Am J Hematol. 2006;81:484–491
  17. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937–951
  18. Slovak ML, Gundacker H, Bloomfield CD, et al. A retrospective study of 69 patients with t(6;9)(p23;q34) AML emphasizes the need for a prospective, multicenter initiative for rare ‘poor prognosis’ myeloid malignancies. Leukemia. 2006;20:1295–1297
  19. Mazzella FM, Kowal-Vern A, Shrit MA, et al. Effects of multidrug resistance gene expression in acute erythroleukemia. Mod Pathol. 2000;13:407–413
  20. Bacher U, Haferlach C, Alpermann T, et al. Comparison of genetic and clinical aspects in patients with acute myeloid leukemia and myelodysplastic syndromes all demonstrating more than 50% of bone marrow erythropoietic cells. Haematologica. 2011;[Epub ahead of print].
  21. Falini B, Macijewski K, Weiss T, et al. Multilineage dysplasia has no impact on biologic, clinicopathologic, and prognostic features of AML with mutated nucleophosmin (NPM1). Blood. 2010;115:3776–3786
  22. Singh ZN, Huo D, Anastasi J, et al. Therapy-related myelodysplastic syndrome: morphologic subclassification may not be clinically relevant. Am J Clin Pathol. 2007;127:197–205
  23. Kantarjian HM, Keating MJ, Walters RS, et al. Therapy-related leukemia and myelodysplastic syndrome: clinical, cytogenetic, and prognostic features. J Clin Oncol. 1986;4:1748–1757
  24. Weinberg OK, Seetharam M, Ren L, et al. Clinical characterization of acute myeloid leukemia with myelodysplasia-related changes as defined by the 2008 WHO classification system. Blood. 2009;113:1906–1908
  25. Hasserjian RP, Zuo Z, Garcia C, et al. Acute erythroid leukemia: a reassessment using criteria refined in the 2008 WHO classification. Blood. 2010;115:1985–1992
  26. Wang SA, Tang G, Fadare O, et al. Erythroid-predominant myelodysplastic syndromes: enumeration of blasts from nonerythroid rather than total marrow cells provides superior risk stratification. Mod Pathol. 2008;21:1394–1402
  27. Smith SM, Le Beau MM, Huo D, et al. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood. 2003;102:43–52
  28. Lessard M, Struski S, Leymarie V, et al. Cytogenetic study of 75 erythroleukemias. Cancer Genet Cytogenet. 2005;163:113–122
  29. Schoch C, Haferlach T. Cytogenetics in acute myeloid leukemia. Curr Oncol Rep. 2002;4:390–397
  30. Santos FP, Faderl S, Garcia-Manero G, et al. Adult acute erythroleukemia: an analysis of 91 patients treated at a single institution. Leukemia. 2009;23:2275–2280
  31. Liu W, Hasserjian RP, Hu Y, et al. Pure erythroid leukemia: a reassessment of the entity using the 2008 World Health Organization classification. Mod Pathol. 2011;24:375–383
  32. Arber DA, Brunning RD, Orazi A, et al. Acute myeloid leukaemia with myelodysplasia-related changes. In:  Swerdlow SH,  Campo E,  Harris NL, et al. editor. 4th ed.. WHO classification of tumours of haematopoietic and lymphoid tissues, vol. Lyon, France: International Agency for Research on Cancer (IARC); 2008;p. 124–126
  33. Cheson BD, Bennett JM, Kantarjian H, et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood. 2000;96:3671–3674
  34. Frohling S, Schlenk RF, Breitruck J, et al. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood. 2002;100:4372–4380
  35. Wang SA, Hasserjian RP, Loew JM, et al. Refractory anemia with ringed sideroblasts associated with marked thrombocytosis harbors JAK2 mutation and shows overlapping myeloproliferative and myelodysplastic features. Leukemia. 2006;20:1641–1644
  36. Heiss S, Erdel M, Gunsilius E, Nachbaur D, Tzankov A. Myelodysplastic/myeloproliferative disease with erythropoietic hyperplasia (erythroid preleukemia) and the unique translocation (8;9)(p23;p24): first description of a case. Hum Pathol. 2005;36:1148–1151
  37. Park S, Picard F, Dreyfus F. Erythroleukemia: a need for a new definition. Leukemia. 2002;16:1399–1401
  38. Park S, Picard F, Guesnu M, et al. Erythroleukaemia and RAEB-t: a same disease?. Leukemia. 2004;18:888–890
  39. Olopade OI, Thangavelu M, Larson RA, et al. Clinical, morphologic, and cytogenetic characteristics of 26 patients with acute erythroblastic leukemia. Blood. 1992;80:2873–2882
  40. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079–2088
  41. Honda Y, Manabe A, Tsuchida M, et al. Clinicopathological characteristics of erythroblast-rich RAEB and AML M6a in children. Int J Hematol. 2008;88:524–529
  42. Bejar R, Stevenson K, Abdel-Wahab O, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med. 2011;364:2496–2506
  43. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood. 1998;92:2322–2333
  44. Breems DA, Van Putten WL, De Greef GE, et al. Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. J Clin Oncol. 2008;26:4791–4797
  45. Goldberg SL, Noel P, Klumpp TR, Dewald GW. The erythroid leukemias: a comparative study of erythroleukemia (FAB M6) and Di Guglielmo disease. Am J Clin Oncol. 1998;21:42–47
  46. Acquaviva C, Gelsi-Boyer V, Birnbaum D. Myelodysplastic syndromes: lost between two states?. Leukemia. 2010;24:1–5
  47. Vardiman JW. The World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues: an overview with emphasis on the myeloid neoplasms. Chem Biol Interact. 2010;184:16–20
  48. Verburgh E, Achten R, Louw VJ, et al. A new disease categorization of low-grade myelodysplastic syndromes based on the expression of cytopenia and dysplasia in one versus more than one lineage improves on the WHO classification. Leukemia. 2007;21:668–677
  49. Ahn JH, Yoon KS, Lee WI, et al. Bone marrow findings before and after treatment with recombinant human erythropoietin in chronic hemodialyzed patients. Clin Nephrol. 1995;43:189–195
  50. Sikole A, Stojanovic A, Polenakovic M, et al. How erythropoietin affects bone marrow of uremic patients. Am J Nephrol. 1997;17:128–136
  51. Hellstrom-Lindberg E, Kanter-Lewensohn L, Ost A. Morphological changes and apoptosis in bone marrow from patients with myelodysplastic syndromes treated with granulocyte-CSF and erythropoietin. Leuk Res. 1997;21:415–425
  52. Hellstrom-Lindberg E, Negrin R, Stein R, et al. Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model. Br J Haematol. 1997;99:344–351
  53. Budde R, Hellerich U. Alcoholic dyshaematopoiesis: morphological features of alcohol-induced bone marrow damage in biopsy sections compared with aspiration smears. Acta Haematol. 1995;94:74–77
  54. Sharp RA, Lowe JG, Johnston RN. Anti-tuberculous drugs and sideroblastic anaemia. Br J Clin Pract. 1990;44:706–707
  55. Broun ER, Greist A, Tricot G, Hoffman R. Excessive zinc ingestion. A reversible cause of sideroblastic anemia and bone marrow depression. JAMA. 1990;264:1441–1443
  56. Gregg XT, Reddy V, Prchal JT. Copper deficiency masquerading as myelodysplastic syndrome. Blood. 2002;100:1493–1495
  57. Natelson EA. Pregnancy-induced pancytopenia with cellular bone marrow: distinctive hematologic features. Am J Med Sci. 2006;332:205–207
  58. Bencaiova G, Breymann C. Acquired sideroblastic anaemia following progesterone treatment in pregnancy. Aust N Z J Obstet Gynaecol. 2009;49:235–236
  59. Bridges KR. Sideroblastic anemia: a mitochondrial disorder. J Pediatr Hematol Oncol. 1997;19:274–278
  60. Magalhaes SM, Duarte FB, Ribeiro SC, Borovik CL, Lorand-Metze I. Sideroblastic anemia following treatment of chronic myeloid leukemia with busulfan. Leukemia. 2000;14:214–215
  61. Ok CY, Medeiros LJ, Hu Y, Bueso-Ramos CE, Wang SA. Transient/reversible ring sideroblasts in bone marrow of patients post cytotoxic therapies for primary malignancies. Leuk Res. 2011;35:1605–1610
  62. Andrieux JL, Demory JL. Karyotype and molecular cytogenetic studies in polycythemia vera. Curr Hematol Rep. 2005;4:224–229
  63. Germing U, Gattermann N, Strupp C, Aivado M, Aul C. Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients. Leuk Res. 2000;24:983–992
  64. Germing U, Strupp C, Kuendgen A, et al. Prospective validation of the WHO proposals for the classification of myelodysplastic syndromes. Haematologica. 2006;91:1596–1604
  65. Miesner M, Haferlach C, Bacher U, et al. Multilineage dysplasia (MLD) in acute myeloid leukemia (AML) correlates with MDS-related cytogenetic abnormalities and a prior history of MDS or MDS/MPN but has no independent prognostic relevance: a comparison of 408 cases classified as “AML not otherwise specified” (AML-NOS) or “AML with myelodysplasia-related changes” (AML-MRC). Blood. 2010;116:2742–2751

PII: S0046-8177(11)00344-3

doi: 10.1016/j.humpath.2011.08.008

Human Pathology
Volume 43, Issue 2 , Pages 153-164 , February 2012

Article Tools

* Image Usage & Resolution